An impact analysis of the implementation of health technology assessment for new treatment of orphan diseases in Japan.

Conclusion: As Japan's CEE is expected to be used only for price adjustment after reimbursement is secured, the approach seems to be similar to the other countries. However, pre-launch clinical data are limited and the peak sales of ODs vary in Japan. Therefore, careful introduction of CEE and multifaceted measures referring the policies for ODs in other countries should be considered. PMID: 31496361 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31496361?dopt=Abstract

Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 10, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research